Perioperative treatment for high-risk liver cancer using HAIC, donafenib, and sintilimab
Part of Cancer clinical trials.
This trial tests a combination of treatments—chemotherapy delivered through the liver artery (HAIC), a targeted drug (donafenib), and an immunotherapy (sintilimab)—given before and after surgery for liver cancer that has a high chance of coming back. The goal is to see if this approach can lower the risk of recurrence.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with hepatocellular carcinoma (a type of liver cancer) that can be surgically removed but has features that make it likely to come back, such as a large tumor (over 5 cm) or multiple tumors.
- Your liver function is good (Child-Pugh class A) and you have not received prior treatment for this cancer.
- You are in generally good health (ECOG score 0 or 1) and expected to live at least 3 more months.
- You do not have cancer that has spread to other parts of the body, severe autoimmune diseases, uncontrolled bleeding, or active infections.
- You are willing to use effective contraception during the study and for 60 days after the last treatment dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether combining two immunotherapy drugs (sintilimab and ipilimumab) with standard procedures to block or destroy the tumor's blood supply can help keep liver cancer from returning after surgery. It is for people whose liver cancer can be removed but has a higher risk of coming back.
This trial tests new treatment plans for people with advanced liver cancer that has worsened after initial therapy. The goal is to find more effective, personalized options based on how your cancer responds.
This trial tests a combined treatment plan—chemo delivered to the liver, targeted therapy, anti-VEGF therapy, and immunotherapy—to control unresectable hepatocellular carcinoma (HCC). It may help shrink tumors or slow progression when surgery isn’t possible.
This trial tests a combination of two drugs (donafenib and sintilimab) plus a liver-directed chemotherapy infusion (HAIC) before surgery for liver cancer that can be removed. The goal is to see if this approach can shrink the tumor and improve outcomes.
This trial tests a combination of liver-directed chemotherapy (HAIC), an immunotherapy drug (sintilimab), and a drug that blocks blood vessel growth (bevacizumab biosimilar) for advanced liver cancer that hasn't been treated with systemic therapy before. The goal is to see if this triple therapy can shrink or control the cancer.
This study tests a combination of liver-directed chemotherapy, targeted therapy, and an immunotherapy drug after surgery for liver cancer that has spread into small blood vessels. The goal is to see if this approach reduces the chance of the cancer coming back.
Hear when a new Hepato Cellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.